Switch to:
More From Other Websites
Motley Fool: Pundits pandering your wealth away Nov 22 2014
Do The IMPROVE-IT Results Offer Promise For Anacetrapib, Another Merck Heart Drug? Nov 21 2014
New data fuels doctors' demands to rewrite U.S. heart guidelines Nov 21 2014
FDA approves new, hard-to-abuse hydrocodone pill Nov 20 2014
Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal Nov 18 2014
AstraZeneca fleshes out standalone strategy Nov 18 2014
TRUMENBA® (Meningococcal Group B Vaccine) is Now Available Nov 18 2014
AstraZeneca’s Soriot Asks for Patience as Pfizer Return Looms Nov 18 2014
Neil Woodford: there's a 50/50 chance Pfizer will come back for AstraZeneca Nov 18 2014
AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer Nov 18 2014
AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer Nov 18 2014
AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer Nov 18 2014
TRUMENBA® (Meningococcal Group B Vaccine) is Now Available Nov 18 2014
Neil Woodford says belief in independent AstraZeneca 'even stronger' Nov 18 2014
Neil Woodford says belief in independent AstraZeneca "even stronger" Nov 18 2014
Neil Woodford says belief in independent AstraZeneca "even stronger" Nov 18 2014
AstraZeneca trumpets progress in cancer, other drugs Nov 18 2014
AstraZeneca trumpets progress in cancer, other drugs Nov 18 2014
Aussie pharma group taking on Pfizer Nov 17 2014
Pfizer sues Aussie pharma group's US arm Nov 17 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

SEENSCO
ReplySEENSCO - 5 months ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK